PR Newswire
24 Jun 2022, 03 GMT+10
ST. CHARLES, Mo., June 24, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a client publication advancing cognitive health research through use of the company's BioMAP Human Phenotypic Profiling and Screening Platform and enzyme assays for neurotransmitter degradation.
Published in BMC Complementary Medicine and Therapies, the work of scientists from The Institute for Biomedical and Bioscience Research, University of Buckingham; the European Genomic Institute for Diabetes, Hospital Claude Huriez; and Sibelius Ltd., identifies changes in biomarkers of inflammation and tissue remodeling that result from the use of sage extract on in vitro, human primary cell translational disease models.
The work documents applicability of the BioMAP Platform beyond standard biopharmaceutical applications and demonstrates the portfolio breadth of Eurofins Discovery in providing testing for life enzyme assays and biomarker screening and profiling services in the neuro-inflammatory and neurodegenerative therapeutic space.
One of the challenges to evaluating potential nutritional interventions for neurodegeneration and other therapeutic areas is assessment of relevant biomarkers in standardized clinically validated in vitro disease models sensitive enough to detect changes in mixtures as well as purified drug candidates. The BioMAP Diversity PLUS Panel can provide this key assessment while covering a broad range of tissue and disease biology. The panel reports on biomarkers common across many diseases that involve inflammation, is validated with clinically approved drugs, and provides results based on advanced data analytics powered by a comprehensive Reference Database.
Additional neurotransmitter metabolism enzyme assays from Eurofins Discovery helped identify specific effects of sage extract, with implications for cognitive performance. Learn more about the Phenotypic Center of Excellence at www.eurofinsdiscoveryservices.com/services/phenotypic-assays.
For further information
eurofinsdiscoveryservices.com
About Eurofins Discovery
Eurofins Discovery is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.
About Eurofins - the global leader in bio-analysis
Eurofins is Testing for Life. With 58,000 staff across a network of 900 laboratories in 54 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
SOURCE Eurofins Discovery
Get a daily dose of Philippine Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Philippine Times.
More InformationMOSCOW, Russia: The UK newspaper, the Telegraph, has been blocked in Russia, following a request from the Russian prosecutor-general.The TASS ...
LAHORE, Pakistan - An Airbus 320 carrying 171 passengers narrowly avoided an accident at Allama Iqbal International Airport, Pakistan's second-largest ...
WASHINGTON, DC - U.S. President Joe Biden on Friday vowed to "do all in my power" to protect a woman's ...
YANGON, Myanmar - According to military-run media, a junta delegation discussed nuclear technology collaboration with a Russian state-owned atomic energy ...
DHAKA, Bangladesh - The United States Agency for International Development (USAID) is providing more than Tk2.3 crore in emergency funding ...
PHNOM PENH, Cambodia: Cambodian villagers on the Mekong River have caught a stingray fish weighing 661 pounds, which is the ...
NEW YORK CITY, New York: Electric vehicle (EV) sales could reach 33 percent globally by 2028, and 54 percent by ...
BERLIN, Germany: To prevent large increases in food prices, officials from G7 countries, including Germany and the UK, will push ...
WASHINGTON D.C.: The U.S. Food and Drug Administration (FDA) is preparing to order Juul Labs to stop selling its e-cigarettes ...
WASHINGTON D.C.: As average home prices surged to a record high, reaching the $400,000 mark for the first time, and ...
MOSCOW, Russia: Russia's consumer price index has fallen by 0.12 percent for the third consecutive week.This drop in the consumer ...
TAIPEI, Taiwan: The American Chamber of Commerce in Taiwan has recommended that the United States "urgently" initiate talks with Taiwan ...